ClinicalTrials.gg
CompletedNCT01577186Updated Jan 17, 2014Results posted

Symptomatic Remission and Social Function in Participants Treated With Paliperidone Extended Release (ER)

A Phase 4 interventional study of Paliperidone ER in Schizophrenia, sponsored by Johnson & Johnson Taiwan Ltd. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-01-17.

Sponsored by Johnson & Johnson Taiwan Ltd (part of Johnson & Johnson) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
480
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 115 studies testing paliperidone in Schizophrenia — 6 open to participants now, 6 under way, none of them phase 3. paliperidone · Schizophrenia.

Enrollment
19th of 115
480 · median 178
Started
2008
with 12 others
Phase 4
42 of 115
5 open now
Registered
76th of 115
by date
Lead sponsor
4 of 115
Johnson & Johnson Taiwan Ltd

Among the 115 studies testing paliperidone in Schizophrenia, this one is the 19th largest by enrollment, is one of 13 that started in 2008, is one of 42 in phase 4, and was the 76th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

6 of the 115 studies testing paliperidone in Schizophrenia are open now, in 4 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About paliperidone

paliperidone: first FDA approval 2006 (INVEGA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 115 studies testing paliperidone in Schizophrenia, or all of them as a file.
02

Study summary

The purpose of this study is to explore the relationship between achieving symptomatic remission status by means of the 8 items of Positive and Negative Syndrome Scale (PANSS), and personal and social functioning by means of the Personal and Social Performance (PSP) scale in participants treated with flexibly dosed paliperidone ER.

Read the detailed description

This is an open label (all people know the identity of the intervention), multicenter (when more than one hospital or medical school team work on a medical research study) and prospective (study following participants forward in time) 12-week study. Participants can be either in- or outpatients. The total study duration will be 12 weeks for each participant and will include following visits: Screening, Week 0, 4, 8, and 12 (end of treatment or early withdrawal). Throughout the study, participants will receive paliperidone ER in a flexible dosing range of 3 to 12 milligram per day (mg/day). Efficacy will primarily be evaluated by PANSS and PSP scale. Participants' safety will also be monitored throughout the study.

03

Conditions studied

  • Schizophrenia

Browse trials for

Keywords

  • Schizophrenia
  • Paliperidone Extended Release
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who meet the , 4th edition (DSM-IV) criteria for schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment from reality, often with delusions and hallucinations, and withdrawal into the self)
  • Participant is drug naive or participant's previous treatment is considered unsuccessful due to one or more of the following reasons: lack of efficacy, lack of tolerability or safety, lack of compliance and/or other reasons
  • Participants or their legally acceptable representatives had signed an document indicating that they understand the purpose of and procedures required for the study and were willing to participate in the study
  • Women must be for at least 1 year, surgically sterile, abstinent, or, if sexually active, agree to practice an effective method of before entry and throughout the study and must have a negative urine pregnancy test at screening

Exclusion criteria

Exclusion Criteria:

  • Participants with use of clozapine, paliperidone extended release (ER), any conventional depot neuroleptic or Risperdal CONSTA during the last 3 months
  • Participants with serious unstable medical condition, including known laboratory abnormalities
  • Participants with history of neuroleptic malignant syndrome (high fever, rigid muscles, shaking, confusion, sweating more than usual, increased heart rate or blood pressure, or muscle pain or weakness)
  • Participants with known to paliperidone ER or risperidone
  • Participants with inability to swallow the whole study medication tablet with aid of water
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
480 participants (actual)

Study arms

  • Experimental
    Paliperidone Extended Release (ER)

    Drug: Paliperidone ER

Interventions

  • Participants will receive paliperidone ER tablet in flexible dose range of 3 to 12 milligram per day (mg/day) orally once daily up to Week 12 as per Investigator's discretion.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Symptomatic Remission by Means of Positive and Negative Syndrome Scale (PANSS)

    The PANSS is a 30-item scale to assess the neuropsychiatric symptoms of schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment from reality, often with delusions and hallucinations, and withdrawal into the self). The PANSS provides a total score and scores for 3 subscales, the positive subscale (7 items), the negative subscale (7 items), and the general psychopathology subscale (16 items), each item scored on a scale of 1 (absent), 2 (minimal), 3 (mild), 4 (moderate), 5 (moderately severe), 6 (severe) and 7 (extreme). The total score ranges from 30 to 210 and higher score indicates greater severity. Symptomatic remission was defined as achieving intensity level of mild or moderate on PANSS scale by all 8 items as the determinants for symptomatic remission: delusions, unusual thought content, hallucinatory behavior, conceptual disorganization, mannerisms/posturing, blunted affect, social withdrawal, lack of spontaneity.

    Time frame: End of study (Up to Week 12)

  2. Percentage of Participants Achieving Improvement in Personal and Social Performance (PSP) Score by at Least One Category on PSP Scale

    The PSP is 100-point validated clinician-rated scale that assesses degree of difficulty in 4 areas of functioning: socially useful activities, personal and social relationships, self-care, disturbing and aggressive behaviors rated on 6-point scale (1=absent to 6=very severe).Total transformed score from 1 to 100 is generated from raw score based on clinical interpretation of scores generated in 4 areas of functioning, with higher transformed score indicating better function. Total score is divided into 3 levels: 71-100 (mild difficulty); 31-70 (marked difficulty) and 1-30 (severe difficulty). Percentage of participants achieving improvement in PSP score by at least one category was reported.

    Time frame: End of study (Up to Week 12)

Secondary outcomes

  1. Social Functioning Scale (SFS) Score

    The SFS is a 36-item scale designed to assess social functioning in schizophrenia. It assesses abilities and performance in seven areas: social engagement, interpersonal communication, activities of daily living, recreation, social activities, competence at independent living, and occupation/employment. Total score ranges from 1 to 100 where higher score indicates a more favorable health state.

    Time frame: End of study (Up to Week 12)

Other outcomes

  1. Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 12

    The PANSS is a 30-item scale to assess the neuropsychiatric symptoms of schizophrenia. The PANSS provides a total score and scores for 3 subscales, the positive subscale (7 items), the negative subscale (7 items), and the general psychopathology subscale (16 items), each item scored on a scale of 1 (absent) to 7 (extreme). The total score ranges from 30 to 210 and higher score indicates greater severity.

    Time frame: Baseline, Week 12

  2. Change From Baseline in Total Personal and Social Performance (PSP) Score at Week 12

    The PSP is 100-point validated clinician-rated scale that assesses degree of difficulty in 4 areas of functioning: socially useful activities, personal and social relationships, self-care, disturbing and aggressive behaviors rated on 6-point scale (1=absent to 6=very severe).Total transformed score from 1 to 100 is generated from raw score based on clinical interpretation of scores generated in 4 areas of functioning, with higher transformed score indicating better function. Total score is divided into 3 levels: 71-100 (mild difficulty); 31-70 (marked difficulty) and 1-30 (severe difficulty).

    Time frame: Baseline, Week 12

07

Results

Posted Jan 17, 2014
Limitations and caveats
Some Adverse Events summaries were reported based on estimates due to the fact that they were not prepared in the original study report and the relevant definitions of the data elements were not available for these summaries to be regenerated.

Participant flow

Participant flow — Overall Study
MilestonePaliperidone ER
Started480
Completed350
Not completed130
Withdrew: Adverse event23
Withdrew: Death1
Withdrew: Lost to follow-up28
Withdrew: Withdrawal by subject35
Withdrew: Insufficient response18
Withdrew: Ineligible to continue15
Withdrew: Non-compliant8
Withdrew: Other2

Outcome measures

PrimaryPercentage of Participants Achieving Symptomatic Remission by Means of Positive and Negative Syndrome Scale (PANSS)

The PANSS is a 30-item scale to assess the neuropsychiatric symptoms of schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment from reality, often with delusions and hallucinations, and withdrawal into the self). The PANSS provides a total score and scores for 3 subscales, the positive subscale (7 items), the negative subscale (7 items), and the general psychopathology subscale (16 items), each item scored on a scale of 1 (absent), 2 (minimal), 3 (mild), 4 (moderate), 5 (moderately severe), 6 (severe) and 7 (extreme). The total score ranges from 30 to 210 and higher score indicates greater severity. Symptomatic remission was defined as achieving intensity level of mild or moderate on PANSS scale by all 8 items as the determinants for symptomatic remission: delusions, unusual thought content, hallucinatory behavior, conceptual disorganization, mannerisms/posturing, blunted affect, social withdrawal, lack of spontaneity.

Time frame:
End of study (Up to Week 12)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Symptomatic Remission by Means of Positive and Negative Syndrome Scale (PANSS)
percentage of participantsPaliperidone Extended Release (ER)
Percentage of Participants Achieving Symptomatic Remission by Means of Positive and Negative Syndrome Scale (PANSS)11.74 (8.84 to 15.18)
SecondarySocial Functioning Scale (SFS) Score

The SFS is a 36-item scale designed to assess social functioning in schizophrenia. It assesses abilities and performance in seven areas: social engagement, interpersonal communication, activities of daily living, recreation, social activities, competence at independent living, and occupation/employment. Total score ranges from 1 to 100 where higher score indicates a more favorable health state.

Time frame:
End of study (Up to Week 12)
Reported as:
Mean · units on a scale
Social Functioning Scale (SFS) Score
units on a scalePaliperidone Extended Release (ER)
Social Functioning Scale (SFS) Score44.99 ± 19.05
PrimaryPercentage of Participants Achieving Improvement in Personal and Social Performance (PSP) Score by at Least One Category on PSP Scale

The PSP is 100-point validated clinician-rated scale that assesses degree of difficulty in 4 areas of functioning: socially useful activities, personal and social relationships, self-care, disturbing and aggressive behaviors rated on 6-point scale (1=absent to 6=very severe).Total transformed score from 1 to 100 is generated from raw score based on clinical interpretation of scores generated in 4 areas of functioning, with higher transformed score indicating better function. Total score is divided into 3 levels: 71-100 (mild difficulty); 31-70 (marked difficulty) and 1-30 (severe difficulty). Percentage of participants achieving improvement in PSP score by at least one category was reported.

Time frame:
End of study (Up to Week 12)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Improvement in Personal and Social Performance (PSP) Score by at Least One Category on PSP Scale
percentage of participantsPaliperidone Extended Release (ER)
Percentage of Participants Achieving Improvement in Personal and Social Performance (PSP) Score by at Least One Category on PSP Scale47.42 (42.59 to 52.28)
Other pre-specifiedChange From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 12

The PANSS is a 30-item scale to assess the neuropsychiatric symptoms of schizophrenia. The PANSS provides a total score and scores for 3 subscales, the positive subscale (7 items), the negative subscale (7 items), and the general psychopathology subscale (16 items), each item scored on a scale of 1 (absent) to 7 (extreme). The total score ranges from 30 to 210 and higher score indicates greater severity.

Time frame:
Baseline, Week 12
Reported as:
Mean · units on a scale
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 12
units on a scalePaliperidone Extended Release (ER)
Baseline (n=426)89.88 ± 29.60
Change at Week 12 (n=350)-16.07 ± 19.64
Other pre-specifiedChange From Baseline in Total Personal and Social Performance (PSP) Score at Week 12

The PSP is 100-point validated clinician-rated scale that assesses degree of difficulty in 4 areas of functioning: socially useful activities, personal and social relationships, self-care, disturbing and aggressive behaviors rated on 6-point scale (1=absent to 6=very severe).Total transformed score from 1 to 100 is generated from raw score based on clinical interpretation of scores generated in 4 areas of functioning, with higher transformed score indicating better function. Total score is divided into 3 levels: 71-100 (mild difficulty); 31-70 (marked difficulty) and 1-30 (severe difficulty).

Time frame:
Baseline, Week 12
Reported as:
Mean · units on a scale
Change From Baseline in Total Personal and Social Performance (PSP) Score at Week 12
units on a scalePaliperidone Extended Release (ER)
Baseline (n=426)47.07 ± 16.34
Change at Week 12 (n=350)9.05 ± 12.55

Adverse events

Collected over 12 weeks. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Paliperidone ER—37/480 (7.7%)169/480 (35.2%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventPaliperidone ER
SchizophreniaPsychiatric disorders27/480
Hallucination, AuditoryPsychiatric disorders2/480
Supraventricular TachycardiaCardiac disorders1/480
Pulmonary TuberculosisInfections and infestations1/480
Femur FractureInjury, poisoning and procedural complications1/480
AggressionPsychiatric disorders1/480
Alcohol AbusePsychiatric disorders1/480
Completed SuicidePsychiatric disorders1/480
Drug AbusePsychiatric disorders1/480
Impulsive BehaviourPsychiatric disorders1/480
Most frequent other events
Showing 10 of 11
Most frequent other events
EventPaliperidone ER
Extrapyramidal DisorderNervous system disorders56/480
Upper Respiratory Tract InfectionInfections and infestations32/480
TremorNervous system disorders23/480
InsomniaPsychiatric disorders21/480
DizzinessNervous system disorders20/480
ConstipationGastrointestinal disorders15/480
Weight IncreasedInvestigations14/480
AnxietyPsychiatric disorders12/480
NasopharyngitisInfections and infestations11/480
HeadacheNervous system disorders10/480

Baseline characteristics

Age, Continuous
Age, Continuous(years)Paliperidone ER
Mean40.3 ± 10.62
Sex: Female, Male
Sex: Female, Male(Participants)Paliperidone ER
Female218
Male262
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2008, a primary completion of Jun 2009 and a completion of Jun 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2014, 4 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 12, 2012
First posted
Apr 13, 2012
Start
Jul 2008
Primary completionActual
Jun 2009
CompletionActual
Jun 2009
Results first posted
Jan 17, 2014
Last update
Jan 17, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 17, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01577186
Responsible party
Sponsor
First posted
Apr 13, 2012
Start date
Jul 2008
Primary completion
Jun 2009
Completion
Jun 2009
Results posted
Jan 17, 2014
Last update
Jan 17, 2014

Study contacts

Johnson & Johnson Taiwan Ltd Clinical Trial
study director · Johnson & Johnson Taiwan Ltd

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Paliperidone

Start the discussion